Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05121038 · ClinicalTrials.gov registry record · Phase 1
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
A Phase 1 study of Colon Cancer and Pancreas Cancer, sponsored by Anup Kasi.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT05121038 is a Phase 1 study of Colon Cancer and Pancreas Cancer that is active but no longer recruiting, run by Anup Kasi. The registered enrollment target is 50 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05121038, a Phase 1 study of Colon Cancer and Pancreas Cancer, is active but no longer recruiting, sponsored by Anup Kasi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers
Conditions Studied
Interventions
- DRUG Panitumumab
- DRUG Folfirinox
- DRUG CEND-1
Study Locations (3)
Kansas
- The University of Kansas Cancer Center (KUCC) - Fairway
- The University of Kansas Cancer Center, Westwood Campus - Kansas City
Missouri
- The University of Kansas Medical Center - North Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05121038
The ClinicalTrials.gov registry entry for NCT05121038 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Anup Kasi, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Colon Cancer appearing as the primary indexed condition, and to 3 interventions - of which Panitumumab is the first listed.
NCT05121038 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Missouri.
Frequently Asked Questions
What is clinical trial NCT05121038 about?
NCT05121038 is a clinical study titled "CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab". This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers
What is the current status of trial NCT05121038?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2021-10-20. Estimated completion is 2026-09.
What conditions does trial NCT05121038 study?
This clinical trial studies the following conditions: Colon Cancer, Pancreas Cancer, Digestive Cancer.
What interventions are being tested in trial NCT05121038?
The interventions under investigation include: Panitumumab (DRUG), Folfirinox (DRUG), CEND-1 (DRUG).
Who is sponsoring clinical trial NCT05121038?
This trial is sponsored by Anup Kasi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05121038 being conducted?
This trial has 3 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
RECRUITING · Phase 1
-
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.